MedPath

Sonlicromanol

Generic Name
Sonlicromanol
Drug Type
Small Molecule
Chemical Formula
C19H28N2O3
CAS Number
1541170-75-5
Unique Ingredient Identifier
JCU3O35RDS

Overview

Sonlicromanol is under investigation in clinical trial NCT04165239 (The KHENERGYZE Study).

Indication

No indication information available.

Associated Conditions

No associated conditions information available.

Research Report

Published: May 19, 2025

Sonlicromanol (DB16333): A Comprehensive Clinical and Scientific Review

1. Sonlicromanol: An Overview

1.1. Introduction to Sonlicromanol (KH176)

Sonlicromanol, also identified by its development code KH176, is an orally administered small molecule drug candidate currently under investigation.[1] It is being developed as a potentially first-in-class, disease-modifying therapy for primary mitochondrial diseases (PMD), a group of rare and often devastating conditions with limited treatment options.[3] Sonlicromanol is considered one of the most clinically advanced drug candidates for PMD currently in development.[3]

The primary developmental focus for Sonlicromanol is on patients with PMD arising from the m.3243A>G mutation in the mitochondrial MT-TL1 gene. This specific genetic variation is the most common cause of PMD and is associated with a spectrum of clinical presentations, including Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes (MELAS), Maternally Inherited Diabetes and Deafness (MIDD), mixed phenotypes (MP), and Chronic Progressive External Ophthalmoplegia (CPEO).[1] This targeted approach towards a genetically defined subgroup, while addressing the most prevalent form of PMD, is strategically significant. Focusing on a specific mutation allows for a more homogeneous patient population in clinical trials, which can be particularly advantageous in the context of rare diseases where patient numbers are inherently small. Such precision may reduce variability in patient responses and enhance the statistical power of studies to detect a therapeutic effect, aligning with the principles of personalized medicine.

1.2. Chemical Properties and Formulation

Sonlicromanol is classified as a small molecule therapeutic. Its fundamental chemical and physical properties are summarized below.

Table 1: Sonlicromanol - Key Identifiers and Properties

Continue reading the full research report

FDA Drug Approvals

Approved Product
Manufacturer
NDC Code
Route
Strength
Effective Date
No FDA approvals found for this drug.

EMA Drug Approvals

Approved Product
Authorization Holder
Status
Issued Date
No EMA approvals found for this drug.

HSA Drug Approvals

Approved Product
Manufacturer
Approval Number
Dosage Form
Strength
Approval Date
No HSA approvals found for this drug.

NMPA Drug Approvals

Approved Product
Company
Approval Number
Drug Type
Dosage Form
Approval Date
No NMPA approvals found for this drug.

PPB Drug Approvals

Approved Product
Registration No.
Company
Licence No.
Strength
Registration Date
No PPB approvals found for this drug.

TGA Drug Approvals

Approved Product
ARTG ID
Sponsor
Registration Type
Status
Registration Date
No TGA approvals found for this drug.

Health Canada Drug Approvals

Approved Product
Company
DIN
Dosage Form
Strength
Market Date
No Health Canada approvals found for this drug.

CIMA AEMPS Drug Approvals

Approved Product
Company
Registration Number
Pharmaceutical Form
Prescription Type
Status
No CIMA AEMPS (Spain) approvals found for this drug.

Philippines FDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Philippines FDA approvals found for this drug.

Saudi SFDA Drug Approvals

Approved Product
Company
License Number
Dosage Form
Strength
Approval Date
No Saudi SFDA approvals found for this drug.

Malaysia NPRA Drug Approvals

Approved Product
Company
Registration Number
Dosage Form
Strength
Approval Date
No Malaysia NPRA approvals found for this drug.

UK EMC Drug Information

Medicine Name
MA Holder
MA Number
Pharmaceutical Form
Active Ingredient
Authorization Date
No UK EMC drug information found for this drug.

Help Us Improve

Your feedback helps us provide better drug information and insights.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.